Manganese-Zeolitic Imidazolate Frameworks-90 with High Blood Circulation Stability for MRI-Guided Tumor Therapy

Jiang, Zhenqi; Yuan, Bo; Qiu, Nianxiang; Wang, Yinjie; Sun, Li; Wei, Zhenni; Li, Yanyin; Zheng, Jianjun; Jin, Yinhua; Li, Yong; Du, Shiyu; Li, Juan; Wu, Aiguo

doi:10.1007/s40820-019-0292-y

Cited by 45 publications

(30 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a famous porous material, zeolitic imidazole frameworks (ZIFs) have shown great potential in gas separation [ 1 , 2 ], catalysis [ 3 ], sensors [ 4 , 5 ], and drug delivery [ 6 , 7 ], for their tunable pore sizes, high surface areas, and structural diversity [ 8 , 9 ]. The high drug loading, stability during blood circulation, and pH-responsive drug release in tumor expand their application in cancer therapy [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

“…ZIF-8 has also been widely used in tumor imaging and therapy [ 15 ] as an ideal vehicle. However, many undesirable outcomes still hamper the in vivo application of ZIFs in biomedicine, such as fast drug release during circulation [ 7 , 10 ], unexpected toxicity to mice major organs [ 16 ], undesirable long-term accumulation in the lung [ 10 ], and even death. Some researchers have explored surface modification [ 16 ], metal-oxide coating [ 17 ], etc., as strategies to ameliorate these side effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo

Jiang

Wei

et al. 2021

Bioactive Materials

Self Cite

View full text Add to dashboard Cite

Zeolitic Imidazole Frameworks (ZIFs) are widely applied in nanomedicine for their high drug loading, suitable pore size, pH-responsive drug release, and so on. However, fast drug release during circulation, unexpected toxicity to mice major organs, undesirable long-term accumulation in the lung and even death currently hinder their in vivo biomedical applications. Herein, we report an amorphous ZIF-8 (aZIF-8) with high loading of 5-Fu through pressure-induced amorphization. This nano-system avoids early drug release during circulation and provides tumor microenvironment-responsive drug release with improved in vitro cell viability, and survival rate in in vivo evaluations as compared to ZIF-8. Furthermore, aZIF-8 shows longer blood circulation and lower lung accumulation than ZIF-8 at same injected doses. Less drug release during circulation, longer blood circulation, and better biocompatibility of aZIF-8/5-Fu significantly improves its therapeutic efficacy in ECA-109 tumor-bearing mouse, and result in 100% survival rate over 50 days after treatment. Therefore, aZIF-8 with favorable biocompatibility and long blood circulation is expected to be a promising nano-system for efficacious cancer therapy in vivo .

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo

Jiang

Wei

et al. 2021

Bioactive Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…[33] Jiang et al synthesized manganese-ZIF-90 for MRI-guided tumor therapy. [42] Xing et al encapsulated cisplatin in ZIF-90 for platinum-resistant ovarian cancer therapy. [43] Moreover, it is also widely studied in the field of imaging, Zou et al loaded with an enzyme-responsive organic probe in ZIF-90 Figure 1.…”

Section: Atp Responsive Drug Release Behavior In Vitromentioning

confidence: 99%

Mitochondrial Metabolism Targeted Nanoplatform for Efficient Triple‐Negative Breast Cancer Combination Therapy

Liu

Lin

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Tumor reprogram pathway of mitochondrial metabolism is an emerging approach for malignant tumor treatment, such as triple-negative breast cancer. In this study, a tumor/mitochondria cascaded targeting, adenosine-triphosphate (ATP) responsive nanocarrier of zeolitic imidazolate framework-90 (ZIF-90) for breast cancer combination therapy is reported. Atovaquone (AVO) and hemin are loaded into ZIF-90, then a peptide iRGD with tumor-targeting ability is modified on the ZIF-90 nanoplatform. Hemin can specifically degrade BTB and CNC homology1 (BACH1), resulting in the changes of mitochondrial metabolism, and AVO acts as the inhibitor of the electron transport chain (ETC). The degradation of BACH1 using hemin can effectively improve the anti-tumor efficiency of mitochondrial metabolism inhibitor AVO, by increasing dependency on mitochondrial respiration. This nanoplatform displays both tumor-targeting and mitochondria-targeting capacity with high level of ATP responsive drug release behavior. The specific characteristic of mitochondria-targeting ability of this nanoplatform can increase the accumulation of AVO in the mitochondria, and in turn, can effectively improve the inhibition of the ETC. Both in vitro and in vivo results reveal that this composite nanocarrier has excellent tumor inhibition ability with limited side effects. Accordingly, this study provides an attractive strategy in the mitochondrial metabolism for cancer targeted therapy.

show abstract

“…Whereas the former shorten the longitudinal relaxation times ( T 1 ) to produce bright signals,11,12 the latter generate dark signals by shortening transversal relaxation times ( T 2 ) 13,14. Among them, the paramagnetic metal ions of Gd (III) and manganese (II) are commonly used to form T 1 contrast agents,15 and the most widely used one is the organometallic complex of Gd, such as Gd‐DTPA (diethylene triamine pentacetate acid, DTPA) 16,17. However, the U.S. Food and Drug Administration has issued a public health warning about Gd chelates, which are associated with the popular nephrogenic systemic fibrosis 18.…”

Section: Introductionmentioning

confidence: 99%

Ten‐Gram‐Scale Facile Synthesis of Organogadolinium Complex Nanoparticles for Tumor Diagnosis

Wei

Jiang

Pan

et al. 2020

Small

Self Cite

View full text Add to dashboard Cite

The market of available contrast agents for clinical magnetic resonance imaging (MRI) has been dominated by gadolinium (Gd) chelates based T1 contrast agents for decades. However, there are growing concerns about their safety because they are retained in the body and are nephrotoxic, which necessitated a warning by the U.S. Food and Drug Administration against the use of such contrast agents. To ameliorate these problems, it is necessary to improve the MRI efficiency of such contrast agents to allow the administration of much reduced dosages. In this study, a ten‐gram‐scale facile method is developed to synthesize organogadolinium complex nanoparticles (i.e., reductive bovine serum albumin stabilized Gd‐salicylate nanoparticles, GdSalNPs‐rBSA) with high r1 value of 19.51 mm−1 s−1 and very low r2/r1 ratio of 1.21 (B0 = 1.5 T) for high‐contrast T1‐weighted MRI of tumors. The GdSalNPs‐rBSA nanoparticles possess more advantages including low synthesis cost (≈0.54 USD per g), long in vivo circulation time (t1/2 = 6.13 h), almost no Gd3+ release, and excellent biosafety. Moreover, the GdSalNPs‐rBSA nanoparticles demonstrate excellent in vivo MRI contrast enhancement (signal‐to‐noise ratio (ΔSNR) ≈ 220%) for tumor diagnosis.

show abstract

Manganese-Zeolitic Imidazolate Frameworks-90 with High Blood Circulation Stability for MRI-Guided Tumor Therapy

Cited by 45 publications

References 52 publications

Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo

Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo

Mitochondrial Metabolism Targeted Nanoplatform for Efficient Triple‐Negative Breast Cancer Combination Therapy

Ten‐Gram‐Scale Facile Synthesis of Organogadolinium Complex Nanoparticles for Tumor Diagnosis

Contact Info

Product

Resources

About